Toripalimab: First Global Approval

Safety and clinical activity with an anti-PD-1 antibody JS001 in advanced melanoma or urologic cancer patients

(2019) Bixia Tang et al.   Journal of Hematology & Oncology

A phase II study of JS001, a humanized PD-1 mAb, in patients with advanced melanoma in China.

(2018) Zhihong Chi et al.   JOURNAL OF CLINICAL ONCOLOGY

A phase Ib study of JS001, a humanized IgG4 mAb against programmed death-1 (PD-1) combination with axitinib in patients with metastatic mucosal melanoma.

(2018) Jun Guo et al.   JOURNAL OF CLINICAL ONCOLOGY

Effect of JS001, a monoclonal antibody targeting programed death-1 (PD-1), on responses and disease control in patients with advanced or refractory alveolar soft part sarcoma: Results from a phase 1 trial.

(2018) Sheng Yang et al.   JOURNAL OF CLINICAL ONCOLOGY

Preliminary results from patients with metastatic urothelial carcinoma (UC) in a phase 2 study of JS001, an anti-PD-1 monoclonal antibody.

(2018) Xinan Sheng et al.   JOURNAL OF CLINICAL ONCOLOGY

Prevalence of BRAF V600E mutation in Chinese melanoma patients: Large scale analysis of BRAF and NRAS mutations in a 432-case cohort

(2011) Lu Si et al.   EUROPEAN JOURNAL OF CANCER